CDNF (cerebral dopamine neurotrophic factor)

Evidence outlook · lead readout

NCT03775538 · Parkinson Disease, Movement Disorders, Neuro-Degenerative Disease, Nervous System Diseases, Brain Diseases

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT03775538: The study continued participants from HP-CD-CL-2002 and used randomization and quadruple masking, but it compared two CDNF doses without a placebo or usual-care control and enrolled only 15 participants. Its primary outcomes were safety and tolerability measures, and no primary-endpoint results are posted, so whether the study met its objectives is unknown.